MarketCap
Facebook
X
Telegram
Satsuma Pharmaceuticals Gesamtverbindlichkeiten | STSA
Gesamtverbindlichkeiten Jährlich Satsuma Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.12 M | 8.49 M | 9.1 M | 10.9 M | 6.86 M | 7.42 M | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 10.9 M | 6.86 M | 8.49 M |
Gesamtverbindlichkeiten Vierteljährlich Satsuma Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.83 M | 8.12 M | 6.66 M | 7.96 M | 6.69 M | 8.49 M | 6.62 M | 7.58 M | 5.91 M | 9.1 M | 9.23 M | 8.68 M | 9.73 M | 10.9 M | 9.42 M | 10.9 M | 10.9 M | 6.86 M | 6.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 10.9 M | 5.83 M | 8.24 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
UroGen Pharma Ltd.
URGN
|
306 M | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
23.8 M | $ 13.91 | 1.9 % | $ 1.24 B |  USA |
 |
ARCA biopharma
ABIO
|
16.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
2.76 M | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
12.6 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
705 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
9.71 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
57.9 M | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
3.73 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
11.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
29.9 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
3.14 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
1.34 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.34 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
4.66 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
17.2 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
19 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
768 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
89.7 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
10.7 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
115 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
19.8 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
676 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
62.1 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
20.1 M | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
37.3 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
20.2 M | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
3.86 M | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
1.3 B | $ 10.15 | -6.8 % | $ 1.64 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
402 K | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
1.45 M | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
16.6 M | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
338 M | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
130 M | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
6.57 M | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
1.77 M | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
37.5 M | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
640 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
5.79 M | - | 0.43 % | $ 12 M | USA |